FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 10/2023”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the US-Biotech sector.
As of the tip of October 2023, we determine the next present VC traits within the US-Biotech sector:
- In 2023, total Biotech funding within the USA has reached USD 19,658m
- In comparison with September 2022 the financing quantity decreased by virtually 29% (27,667m vs. 19,658m)
- The highest 5 offers exceed USD 273m every, the biggest transaction amounted to USD 401m with ElevateBio
- Aiolos Bio has the best transaction Quantity of USD 245m in October, adopted by MapLight USD 225m and Rakuten Medical USD 182m
- ARCH Enterprise Companions (USA) is main the Prime 5 Buyers (by deal quantity), adopted by RA Capital Administration (USA) and Google Ventures (USA)
- As a sign oncology information the best funding exercise
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.